Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Inclusion Criteria:

• Gout subjects meeting 2015 ACR/EULAR Gout Classification Criteria with inadequateurate-lowering response

• Subject has had at least 2 gout flares in the previous 12 months.

• Body Mass Index (BMI) between 18.0 and 45.0 kg/m2 (inclusive).

• Male and Female Subjects must agree to abstain or use effective contraceptionmethods from the time of signing ICF and for the duration of study participationthrough 30 days after the last dose of study drug.

• Subjects must have adequate clinical laboratory and ECG results as assessed by thePrincipal Investigator

Exclusion Criteria:

• Subjects with significant comorbidities, inadequate lab function, current (andwithin the past 5 years) diagnosis of cancer or any condition that, in the judgmentof the investigator, would place him/her at undue risk, or potentially compromisethe results or interpretation of the study.

• Women who are pregnant or breastfeeding